Exact Sciences (EXAS) Offers Promising Early Data for Cologuard 2.0 at ASCO GI - Jefferies
Tweet Send to a Friend
Jefferies analyst Brandon Couillard reiterated a Buy rating and $140.00 price target on Exact Sciences (NASDAQ: EXAS) after the second-gen ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
